Example: biology
Direct Oral Anticoagulants (DOACs) Guide
Anticoagulant, Antiplatelet, NSAID, SSRI, SNRI* may increase bleeding risk P-gp inhibitors§ NVAF: no dose reduction recommended with concomitant use VTE treatment: 30 mg PO once Anticoagulant, Antiplatelet, NSAID* may increase bleeding risk P-gp inducers* avoid use Combined P-gp and strong CYP3A4 inhibitors* avoid use can lead to increased
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Switching To and From Various Anticoagulants - …
www.mplsheart.com26 From To Conversion Recommendation Heparinoids/SC Agents, continued LMWH/ subcutaneous (Enoxaparin, Dalteparin, Fondaparinux) heparin …
Switching To and From Various Anticoagulants
www.mplsheart.comStop rivaroxaban Begin agent at time when next dose of rivaroxaban is due warfarin Stop rivaroxaban Start warfarin and consider starting bridging agent at next rivaroxaban due time Start INR monitoring 2 days after stopping rivaroxaban (INR values drawn sooner may be falsely elevated by rivaroxaban) Stop bridging agent once goal INR is achieved
Major Recommendations for Statin Therapy for ...
www.mplsheart.comGuidance for High-Intensity and Moderate Intensity Statin Dosing High-Intensity Statins • Atorvastatin 40-80 mg • Rosuvastatin 20-40 mg Moderate-Intensity Statins
Related documents
Guideline for the Prevention of Venous Thromboembolism ...
www.health.qld.gov.auAnticoagulated Receiving an anticoagulant (i.e. unfractionated heparin, low molecular weight heparin [dalteparin, enoxaparin, nadroparin], warfarin with INR in therapeutic range, direct oral anticoagulant [apixaban, dabigatran, rivaroxaban], danaparoid, bivalirudin, fondaparinux) Antiplatelet agent Medication that inhibits platelet aggregation.
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euanticoagulant. therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5). Concomitant treatment of ACS with antiplatelet therapy in patients with a prior stroke or a transient ischaemic attack (TIA) (see …